Compliance
What Are the Federal Lobbying Compliance Requirements for Drug Companies? (Plus Recent Agency Activity on Prescription Drug Advertising)
November 19, 2026 | Phil Brown
The FDA's 2027 budget request seeks authority to deem a prescription drug misbranded if its direct-to-consumer ad lacks fair balance and creates a misleading impression about FDA approval, labeled use, or efficacy. This is part of broader FDA drug advertising rules under consideration. FDA's proposed misbranded DTC ads standard builds on a 1969 regulation that already requires broadcast drug ads to present a clear, conspicuous, and neutral disclosure of risks alongside benefit information. The FDA has also proposed eliminating the "adequate provision" standard, which would require broadcast ads to include all relevant risk and safety information within the ad itself rather than directing viewers elsewhere for it. Sens. Durbin and Marshall introduced the Protecting Patients from Deceptive Drug Ads Act, which would require telehealth providers to include summary information in prescription drug ads. Drug companies lobbying Congress on these issues need to understand the Lobbying Disclosure Act requirements, including the 20 percent time threshold, the $16,000 quarterly spending threshold, and the quarterly and semiannual reporting obligations that follow registration.